Expert Interview
A Second View: Evaluating the Future Treatment Landscape for Lipoprotein(a) management and the Potential of Pelacarsen (Novartis), Olpasiran (Amgen), and Lepodisiran (Eli Lilly)
Ticker(s): AMGN, NVS, LLYInstitution: Penn Medicine
- Clinical Associate Professor at the University of Pennsylvania’s Perelman School of Medicine, specializing in preventive cardiology and clinical lipidology at Penn Heart and Vascular Center.
- Manages over 100+ patients for cardiovascular disease
- Fellow of the National Lipid Association and American College of Physicians, authoring over 50 peer-reviewed articles on cardiovascular risk and apolipoprotein B management.
Are You Interested In These Questions?
Slingshot Insights Explained
- Call Date
- Apr 22, 2026
- Call Time
- 03:45 PM EDT
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
